entinostat has been researched along with Body Weight in 2 studies
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In vivo pharmacokinetic data were obtained from 64 adult patients (36 male/28 female; median age, 57 years) receiving MS-275 orally (dose range, 2 to 12 mg/m2)." | 2.72 | Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer. ( Acharya, MR; Figg, WD; Gojo, I; Hwang, K; Karp, JE; Ryan, Q; Sausville, EA; Sparreboom, A; Venitz, J, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chindasub, P | 1 |
| Lindsey, JD | 1 |
| Duong-Polk, K | 1 |
| Leung, CK | 1 |
| Weinreb, RN | 1 |
| Acharya, MR | 1 |
| Karp, JE | 1 |
| Sausville, EA | 1 |
| Hwang, K | 1 |
| Ryan, Q | 1 |
| Gojo, I | 1 |
| Venitz, J | 1 |
| Figg, WD | 1 |
| Sparreboom, A | 1 |
1 trial available for entinostat and Body Weight
| Article | Year |
|---|---|
Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Benzamides; Body Mass Index; Body Su | 2006 |
1 other study available for entinostat and Body Weight
| Article | Year |
|---|---|
Inhibition of histone deacetylases 1 and 3 protects injured retinal ganglion cells.
Topics: Animals; Benzamides; Body Weight; Cell Differentiation; Cell Survival; Female; Green Fluorescent Pro | 2013 |